{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T22:44:24Z","timestamp":1770677064817,"version":"3.49.0"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2011,12,1]],"date-time":"2011-12-01T00:00:00Z","timestamp":1322697600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2011,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>The cytogenetic characteristic of Chronic Myeloid Leukemia (CML) is the formation of the Philadelphia chromosome gene product, BCR-ABL. Given that BCR-ABL is the specific target of Gleevec in CML treatment, we investigated the regulation of the catalytic component of telomerase, hTERT, by BCR-ABL at multiple levels in K562 cells.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>Molecular techniques such as over expression, knockdown, real-time PCR, immunoprecipitation, western blotting, reporter assay, confocal microscopy, telomerase assays and microarray were used to suggest that hTERT expression and activity is modulated by BCR-ABL at multiple levels.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Our results suggest that BCR-ABL plays an important role in regulating hTERT in K562 (BCR-ABL positive human leukemia) cells. When Gleevec inhibited the tyrosine kinase activity of BCR-ABL, phosphorylation of hTERT was downregulated, therefore suggesting a positive correlation between BCR-ABL and hTERT. Gleevec treatment inhibited <jats:italic>hTERT<\/jats:italic> at mRNA level and significantly reduced telomerase activity (TA) in K562 cells, but not in HL60 or Jurkat cells (BCR-ABL negative cells). We also demonstrated that the transcription factor STAT5a plays a critical role in <jats:italic>hTERT<\/jats:italic> gene regulation in K562 cells. Knockdown of STAT5a, but not STAT5b, resulted in a marked downregulation of <jats:italic>hTERT<\/jats:italic> mRNA level, TA and hTERT protein level in K562 cells. Furthermore, translocation of hTERT from nucleoli to nucleoplasm was observed in K562 cells induced by Gleevec.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>Our data reveal that BCR-ABL can regulate TA at multiple levels, including transcription, post-translational level, and proper localization. Thus, suppression of cell growth and induction of apoptosis by Gleevec treatment may be partially due to TA inhibition. Additionally, we have identified STAT5a as critical mediator of the <jats:italic>hTERT<\/jats:italic> gene expression in BCR-ABL positive CML cells, suggesting that targeting STAT5a may be a promising therapeutic strategy for BCR-ABL positive CML patients.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/1471-2407-11-512","type":"journal-article","created":{"date-parts":[[2011,12,9]],"date-time":"2011-12-09T19:15:20Z","timestamp":1323458120000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Regulation of hTERT by BCR-ABL at multiple levels in K562 cells"],"prefix":"10.1186","volume":"11","author":[{"given":"Juin Hsien","family":"Chai","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei Han","family":"Tan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wee Joo","family":"Chng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Baojie","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xueying","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2011,12,9]]},"reference":[{"issue":"8","key":"2995_CR1","doi-asserted-by":"publisher","first-page":"2033","DOI":"10.1172\/JCI31771","volume":"117","author":"PC Nowell","year":"2007","unstructured":"Nowell PC: Discovery of the Philadelphia chromosome: a personal perspective. J Clin Invest. 2007, 117 (8): 2033-2035. 10.1172\/JCI31771.","journal-title":"J Clin Invest"},{"issue":"2","key":"2995_CR2","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/0092-8674(86)90450-2","volume":"47","author":"E Shtivelman","year":"1986","unstructured":"Shtivelman E, Lifshitz B, Gale RP, Roe BA, Canaani E: Alternative splicing of RNAs transcribed from the human abl gene and from the bcr-abl fused gene. Cell. 1986, 47 (2): 277-284. 10.1016\/0092-8674(86)90450-2.","journal-title":"Cell"},{"issue":"4841 Pt 1","key":"2995_CR3","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1126\/science.3422516","volume":"239","author":"SS Clark","year":"1988","unstructured":"Clark SS, McLaughlin J, Timmons M, Pendergast AM, Ben-Neriah Y, Dow LW, Crist W, Rovera G, Smith SD, Witte ON: Expression of a distinctive BCR-ABL oncogene in Ph1-positive acute lymphocytic leukemia (ALL). Science. 1988, 239 (4841 Pt 1): 775-777.","journal-title":"Science"},{"issue":"5405","key":"2995_CR4","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1038\/243290a0","volume":"243","author":"JD Rowley","year":"1973","unstructured":"Rowley JD: Letter: A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature. 1973, 243 (5405): 290-293. 10.1038\/243290a0.","journal-title":"Nature"},{"key":"2995_CR5","first-page":"6","volume":"1","author":"A Butturini","year":"2002","unstructured":"Butturini A, Arlinghaus RB, Gale RP: BCR\/ABL. Encyclopedia of Cancer. 2002, 1: 6-","journal-title":"Encyclopedia of Cancer"},{"issue":"6","key":"2995_CR6","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1038\/nrc2147","volume":"7","author":"JV Melo","year":"2007","unstructured":"Melo JV, Barnes DJ: Chronic myeloid leukaemia as a model of disease evolution in human cancer. Nat Rev Cancer. 2007, 7 (6): 441-453. 10.1038\/nrc2147.","journal-title":"Nat Rev Cancer"},{"issue":"6","key":"2995_CR7","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1182\/blood.V82.6.1838.1838","volume":"82","author":"RA Mandanas","year":"1993","unstructured":"Mandanas RA, Leibowitz DS, Gharehbaghi K, Tauchi T, Burgess GS, Miyazawa K, Jayaram HN, Boswell HS: Role of p21 RAS in p210 bcr-abl transformation of murine myeloid cells. Blood. 1993, 82 (6): 1838-1847.","journal-title":"Blood"},{"issue":"20","key":"2995_CR8","doi-asserted-by":"publisher","first-page":"6151","DOI":"10.1093\/emboj\/16.20.6151","volume":"16","author":"T Skorski","year":"1997","unstructured":"Skorski T, Bellacosa A, Nieborowska-Skorska M, Majewski M, Martinez R, Choi JK, Trotta R, Wlodarski P, Perrotti D, Chan TO, et al: Transformation of hematopoietic cells by BCR\/ABL requires activation of a PI-3 k\/Akt-dependent pathway. EMBO J. 1997, 16 (20): 6151-6161. 10.1093\/emboj\/16.20.6151.","journal-title":"EMBO J"},{"issue":"25","key":"2995_CR9","doi-asserted-by":"publisher","first-page":"11746","DOI":"10.1073\/pnas.92.25.11746","volume":"92","author":"AB Raitano","year":"1995","unstructured":"Raitano AB, Halpern JR, Hambuch TM, Sawyers CL: The Bcr-Abl leukemia oncogene activates Jun kinase and requires Jun for transformation. Proc Natl Acad Sci USA. 1995, 92 (25): 11746-11750. 10.1073\/pnas.92.25.11746.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"6","key":"2995_CR10","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1016\/0092-8674(92)90241-4","volume":"70","author":"CL Sawyers","year":"1992","unstructured":"Sawyers CL, Callahan W, Witte ON: Dominant negative MYC blocks transformation by ABL oncogenes. Cell. 1992, 70 (6): 901-910. 10.1016\/0092-8674(92)90241-4.","journal-title":"Cell"},{"issue":"4946","key":"2995_CR11","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1126\/science.2408149","volume":"247","author":"TG Lugo","year":"1990","unstructured":"Lugo TG, Pendergast AM, Muller AJ, Witte ON: Tyrosine kinase activity and transformation potency of bcr-abl oncogene products. Science. 1990, 247 (4946): 1079-1082. 10.1126\/science.2408149.","journal-title":"Science"},{"issue":"5","key":"2995_CR12","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1038\/nm0596-561","volume":"2","author":"BJ Druker","year":"1996","unstructured":"Druker BJ, Tamura S, Buchdunger E, Ohno S, Segal GM, Fanning S, Zimmermann J, Lydon NB: Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med. 1996, 2 (5): 561-566. 10.1038\/nm0596-561.","journal-title":"Nat Med"},{"key":"2995_CR13","first-page":"57","volume":"21","author":"S John","year":"2001","unstructured":"John S: The molecular biology of cancer. Molecular Aspects of Medicine. 2001, 21: 57-","journal-title":"Molecular Aspects of Medicine"},{"issue":"3","key":"2995_CR14","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1038\/sj.leu.2402848","volume":"17","author":"ME O'Dwyer","year":"2003","unstructured":"O'Dwyer ME, Gatter KM, Loriaux M, Druker BJ, Olson SB, Magenis RE, Lawce H, Mauro MJ, Maziarz RT, Braziel RM: Demonstration of Philadelphia chromosome negative abnormal clones in patients with chronic myelogenous leukemia during major cytogenetic responses induced by imatinib mesylate. Leukemia. 2003, 17 (3): 481-487. 10.1038\/sj.leu.2402848.","journal-title":"Leukemia"},{"issue":"5820","key":"2995_CR15","doi-asserted-by":"publisher","first-page":"1850","DOI":"10.1126\/science.1138596","volume":"315","author":"SB Cohen","year":"2007","unstructured":"Cohen SB, Graham ME, Lovrecz GO, Bache N, Robinson PJ, Reddel RR: Protein composition of catalytically active human telomerase from immortal cells. Science. 2007, 315 (5820): 1850-1853. 10.1126\/science.1138596.","journal-title":"Science"},{"issue":"4","key":"2995_CR16","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1038\/sj.bjc.6604209","volume":"98","author":"JW Shay","year":"2008","unstructured":"Shay JW, Keith WN: Targeting telomerase for cancer therapeutics. Br J Cancer. 2008, 98 (4): 677-683. 10.1038\/sj.bjc.6604209.","journal-title":"Br J Cancer"},{"issue":"5","key":"2995_CR17","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1016\/j.leukres.2003.09.006","volume":"28","author":"O Bock","year":"2004","unstructured":"Bock O, Serinsoz E, Schlue J, Kreipe H: Different expression levels of the telomerase catalytic subunit hTERT in myeloproliferative and myelodysplastic diseases. Leuk Res. 2004, 28 (5): 457-460. 10.1016\/j.leukres.2003.09.006.","journal-title":"Leuk Res"},{"issue":"6743","key":"2995_CR18","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1038\/22780","volume":"400","author":"WC Hahn","year":"1999","unstructured":"Hahn WC, Counter CM, Lundberg AS, Beijersbergen RL, Brooks MW, Weinberg RA: Creation of human tumour cells with defined genetic elements. Nature. 1999, 400 (6743): 464-468. 10.1038\/22780.","journal-title":"Nature"},{"issue":"1","key":"2995_CR19","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/S0959-437X(01)00268-4","volume":"12","author":"DL Aisner","year":"2002","unstructured":"Aisner DL, Wright WE, Shay JW: Telomerase regulation: not just flipping the switch. Curr Opin Genet Dev. 2002, 12 (1): 80-85. 10.1016\/S0959-437X(01)00268-4.","journal-title":"Curr Opin Genet Dev"},{"issue":"19","key":"2995_CR20","doi-asserted-by":"publisher","first-page":"13085","DOI":"10.1074\/jbc.274.19.13085","volume":"274","author":"SS Kang","year":"1999","unstructured":"Kang SS, Kwon T, Kwon DY, Do SI: Akt protein kinase enhances human telomerase activity through phosphorylation of telomerase reverse transcriptase subunit. J Biol Chem. 1999, 274 (19): 13085-13090. 10.1074\/jbc.274.19.13085.","journal-title":"J Biol Chem"},{"issue":"15","key":"2995_CR21","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1096\/fasebj.13.15.2091","volume":"13","author":"JP Liu","year":"1999","unstructured":"Liu JP: Studies of the molecular mechanisms in the regulation of telomerase activity. FASEB J. 1999, 13 (15): 2091-2104.","journal-title":"FASEB J"},{"issue":"3","key":"2995_CR22","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1159\/000084647","volume":"71","author":"B Lankat-Buttgereit","year":"2005","unstructured":"Lankat-Buttgereit B, Horsch D, Barth P, Arnold R, Blocker S, Goke R: Effects of the tyrosine kinase inhibitor imatinib on neuroendocrine tumor cell growth. Digestion. 2005, 71 (3): 131-140. 10.1159\/000084647.","journal-title":"Digestion"},{"issue":"10","key":"2995_CR23","doi-asserted-by":"publisher","first-page":"1881","DOI":"10.1038\/sj.bjc.6602592","volume":"92","author":"O Uziel","year":"2005","unstructured":"Uziel O, Fenig E, Nordenberg J, Beery E, Reshef H, Sandbank J, Birenbaum M, Bakhanashvili M, Yerushalmi R, Luria D, et al: Imatinib mesylate (Gleevec) downregulates telomerase activity and inhibits proliferation in telomerase-expressing cell lines. Br J Cancer. 2005, 92 (10): 1881-1891. 10.1038\/sj.bjc.6602592.","journal-title":"Br J Cancer"},{"issue":"3","key":"2995_CR24","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1016\/j.leukres.2007.07.020","volume":"32","author":"P Wihlidal","year":"2008","unstructured":"Wihlidal P, Karlic H, Pfeilstocker M, Klaushofer K, Varga F: Imatinib mesylate (IM)-induced growth inhibition is associated with production of spliced osteocalcin-mRNA in cell lines. Leuk Res. 2008, 32 (3): 437-443. 10.1016\/j.leukres.2007.07.020.","journal-title":"Leuk Res"},{"issue":"1","key":"2995_CR25","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.exphem.2009.10.005","volume":"38","author":"R Mor-Tzuntz","year":"2010","unstructured":"Mor-Tzuntz R, Uziel O, Shpilberg O, Lahav J, Raanani P, Bakhanashvili M, Rabizadeh E, Zimra Y, Lahav M, Granot G: Effect of imatinib on the signal transduction cascade regulating telomerase activity in K562 (BCR-ABL-positive) cells sensitive and resistant to imatinib. Exp Hematol. 2010, 38 (1): 27-37. 10.1016\/j.exphem.2009.10.005.","journal-title":"Exp Hematol"},{"issue":"4","key":"2995_CR26","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1038\/sj.leu.2404141","volume":"20","author":"LJ Campbell","year":"2006","unstructured":"Campbell LJ, Fidler C, Eagleton H, Peniket A, Kusec R, Gal S, Littlewood TJ, Wainscoat JS, Boultwood J: hTERT, the catalytic component of telomerase, is downregulated in the haematopoietic stem cells of patients with chronic myeloid leukaemia. Leukemia. 2006, 20 (4): 671-679. 10.1038\/sj.leu.2404141.","journal-title":"Leukemia"},{"issue":"7","key":"2995_CR27","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1038\/sj.bjp.0707374","volume":"152","author":"P Phatak","year":"2007","unstructured":"Phatak P, Burger AM: Telomerase and its potential for therapeutic intervention. Br J Pharmacol. 2007, 152 (7): 1003-1011.","journal-title":"Br J Pharmacol"},{"issue":"2","key":"2995_CR28","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1038\/ng1084","volume":"33","author":"DM Baird","year":"2003","unstructured":"Baird DM, Rowson J, Wynford-Thomas D, Kipling D: Extensive allelic variation and ultrashort telomeres in senescent human cells. Nat Genet. 2003, 33 (2): 203-207. 10.1038\/ng1084.","journal-title":"Nat Genet"},{"issue":"2","key":"2995_CR29","doi-asserted-by":"publisher","first-page":"219","DOI":"10.2174\/1566524053586626","volume":"5","author":"OG Opitz","year":"2005","unstructured":"Opitz OG: Telomeres, telomerase and malignant transformation. Curr Mol Med. 2005, 5 (2): 219-226. 10.2174\/1566524053586626.","journal-title":"Curr Mol Med"},{"issue":"7","key":"2995_CR30","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1038\/nrd839","volume":"1","author":"R Capdeville","year":"2002","unstructured":"Capdeville R, Buchdunger E, Zimmermann J, Matter A: Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug. Nat Rev Drug Discov. 2002, 1 (7): 493-502. 10.1038\/nrd839.","journal-title":"Nat Rev Drug Discov"},{"issue":"5","key":"2995_CR31","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1016\/j.exphem.2005.02.002","volume":"33","author":"U Hartmann","year":"2005","unstructured":"Hartmann U, Balabanov S, Ziegler P, Fellenberg J, van der Kuip H, Duyster J, Lipp HP, Bokemeyer C, Kanz L, Brummendorf TH: Telomere length and telomerase activity in the BCR-ABL-transformed murine pro-B cell line BaF3 is unaffected by treatment with imatinib. Experimental Hematology. 2005, 33 (5): 542-549. 10.1016\/j.exphem.2005.02.002.","journal-title":"Experimental Hematology"},{"issue":"23","key":"2995_CR32","doi-asserted-by":"publisher","first-page":"4818","DOI":"10.1093\/nar\/29.23.4818","volume":"29","author":"X Yi","year":"2001","unstructured":"Yi X, Shay JW, Wright WE: Quantitation of telomerase components and hTERT mRNA splicing patterns in immortal human cells. Nucleic Acids Res. 2001, 29 (23): 4818-4825. 10.1093\/nar\/29.23.4818.","journal-title":"Nucleic Acids Res"},{"issue":"7","key":"2995_CR33","doi-asserted-by":"publisher","first-page":"2946","DOI":"10.1182\/blood-2008-01-134692","volume":"112","author":"M Bellon","year":"2008","unstructured":"Bellon M, Nicot C: Central role of PI3K in transcriptional activation of hTERT in HTLV-I-infected cells. Blood. 2008, 112 (7): 2946-2955. 10.1182\/blood-2008-01-134692.","journal-title":"Blood"},{"issue":"12","key":"2995_CR34","doi-asserted-by":"publisher","first-page":"1496","DOI":"10.4161\/cc.6.12.4304","volume":"6","author":"M Nakatake","year":"2007","unstructured":"Nakatake M, Kakiuchi Y, Sasaki N, Murakami-Murofushi K, Yamada O: STAT3 and PKC differentially regulate telomerase activity during megakaryocytic differentiation of K562 cells. Cell Cycle. 2007, 6 (12): 1496-1501.","journal-title":"Cell Cycle"},{"issue":"8","key":"2995_CR35","doi-asserted-by":"publisher","first-page":"2585","DOI":"10.1091\/mbc.E01-11-0107","volume":"13","author":"I Horikawa","year":"2002","unstructured":"Horikawa I, Cable PL, Mazur SJ, Appella E, Afshari CA, Barrett JC: Downstream E-box-mediated regulation of the human telomerase reverse transcriptase (hTERT) gene transcription: evidence for an endogenous mechanism of transcriptional repression. Mol Biol Cell. 2002, 13 (8): 2585-2597. 10.1091\/mbc.E01-11-0107.","journal-title":"Mol Biol Cell"},{"issue":"18","key":"2995_CR36","doi-asserted-by":"publisher","first-page":"1629","DOI":"10.1016\/j.cub.2005.08.036","volume":"15","author":"C Wellbrock","year":"2005","unstructured":"Wellbrock C, Weisser C, Hassel JC, Fischer P, Becker J, Vetter CS, Behrmann I, Kortylewski M, Heinrich PC, Schartl M: STAT5 contributes to interferon resistance of melanoma cells. Curr Biol. 2005, 15 (18): 1629-1639. 10.1016\/j.cub.2005.08.036.","journal-title":"Curr Biol"},{"issue":"8","key":"2995_CR37","doi-asserted-by":"publisher","first-page":"4826","DOI":"10.4049\/jimmunol.166.8.4826","volume":"166","author":"K Liu","year":"2001","unstructured":"Liu K, Hodes RJ, Weng N: Cutting edge: telomerase activation in human T lymphocytes does not require increase in telomerase reverse transcriptase (hTERT) protein but is associated with hTERT phosphorylation and nuclear translocation. J Immunol. 2001, 166 (8): 4826-4830.","journal-title":"J Immunol"},{"issue":"9","key":"2995_CR38","doi-asserted-by":"publisher","first-page":"3038","DOI":"10.1172\/JCI33337","volume":"118","author":"MG Kharas","year":"2008","unstructured":"Kharas MG, Janes MR, Scarfone VM, Lilly MB, Knight ZA, Shokat KM, Fruman DA: Ablation of PI3K blocks BCR-ABL leukemogenesis in mice, and a dual PI3K\/mTOR inhibitor prevents expansion of human BCR-ABL + leukemia cells. J Clin Invest. 2008, 118 (9): 3038-3050. 10.1172\/JCI33337.","journal-title":"J Clin Invest"},{"issue":"5164","key":"2995_CR39","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1126\/science.8197455","volume":"264","author":"JE Darnell Jr","year":"1994","unstructured":"Darnell JE, Kerr IM, Stark GR: Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science. 1994, 264 (5164): 1415-1421. 10.1126\/science.8197455.","journal-title":"Science"},{"issue":"21","key":"2995_CR40","doi-asserted-by":"publisher","first-page":"2474","DOI":"10.1038\/sj.onc.1203527","volume":"19","author":"T Bowman","year":"2000","unstructured":"Bowman T, Garcia R, Turkson J, Jove R: STATs in oncogenesis. Oncogene. 2000, 19 (21): 2474-2488. 10.1038\/sj.onc.1203527.","journal-title":"Oncogene"},{"issue":"12","key":"2995_CR41","doi-asserted-by":"publisher","first-page":"4917","DOI":"10.1182\/blood-2005-10-4110","volume":"107","author":"D Ye","year":"2006","unstructured":"Ye D, Wolff N, Li L, Zhang SM, Ilaria RL: STAT5 signaling is required for the efficient induction and maintenance of CML in mice. Blood. 2006, 107 (12): 4917-4925. 10.1182\/blood-2005-10-4110.","journal-title":"Blood"},{"issue":"49","key":"2995_CR42","doi-asserted-by":"publisher","first-page":"31704","DOI":"10.1074\/jbc.271.49.31704","volume":"271","author":"RL Ilaria Jr","year":"1996","unstructured":"Ilaria RL, Van Etten RA: P210 and P190(BCR\/ABL) induce the tyrosine phosphorylation and DNA binding activity of multiple specific STAT family members. J Biol Chem. 1996, 271 (49): 31704-31710. 10.1074\/jbc.271.49.31704.","journal-title":"J Biol Chem"},{"issue":"2","key":"2995_CR43","first-page":"247","volume":"13","author":"K Shuai","year":"1996","unstructured":"Shuai K, Halpern J, ten Hoeve J, Rao X, Sawyers CL: Constitutive activation of STAT5 by the BCR-ABL oncogene in chronic myelogenous leukemia. Oncogene. 1996, 13 (2): 247-254.","journal-title":"Oncogene"},{"issue":"12","key":"2995_CR44","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.1007\/s000180050393","volume":"55","author":"T Decker","year":"1999","unstructured":"Decker T, Kovarik P: Transcription factor activity of STAT proteins: structural requirements and regulation by phosphorylation and interacting proteins. Cell Mol Life Sci. 1999, 55 (12): 1535-1546. 10.1007\/s000180050393.","journal-title":"Cell Mol Life Sci"},{"issue":"3","key":"2995_CR45","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1002\/emmm.201000062","volume":"2","author":"A Hoelbl","year":"2010","unstructured":"Hoelbl A, Schuster C, Kovacic B, Zhu BM, Wickre M, Hoelzl MA, Fajmann S, Grebien F, Warsch W, Stengl G, et al: Stat5 is indispensable for the maintenance of bcr\/abl-positive leukaemia. EMBO Molecular Medicine. 2010, 2 (3): 98-110. 10.1002\/emmm.201000062.","journal-title":"EMBO Molecular Medicine"},{"issue":"6","key":"2995_CR46","doi-asserted-by":"crossref","first-page":"2118","DOI":"10.1182\/blood.V95.6.2118","volume":"95","author":"C Sillaber","year":"2000","unstructured":"Sillaber C, Gesbert F, Frank DA, Sattler M, Griffin JD: STAT5 activation contributes to growth and viability in Bcr\/Abl-transformed cells. Blood. 2000, 95 (6): 2118-2125.","journal-title":"Blood"},{"issue":"21","key":"2995_CR47","doi-asserted-by":"publisher","first-page":"2566","DOI":"10.1038\/sj.onc.1203523","volume":"19","author":"JX Lin","year":"2000","unstructured":"Lin JX, Leonard WJ: The role of Stat5a and Stat5b in signaling by IL-2 family cytokines. Oncogene. 2000, 19 (21): 2566-2576. 10.1038\/sj.onc.1203523.","journal-title":"Oncogene"},{"issue":"5","key":"2995_CR48","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1016\/S0092-8674(00)81444-0","volume":"93","author":"S Teglund","year":"1998","unstructured":"Teglund S, McKay C, Schuetz E, van Deursen JM, Stravopodis D, Wang DM, Brown M, Bodner S, Grosveld G, Ihle JN: Stat5a and Stat5b proteins have essential and nonessential, or redundant, roles in cytokine responses. Cell. 1998, 93 (5): 841-850. 10.1016\/S0092-8674(00)81444-0.","journal-title":"Cell"},{"issue":"2","key":"2995_CR49","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/S0092-8674(00)81013-2","volume":"98","author":"M Socolovsky","year":"1999","unstructured":"Socolovsky M, Fallon AEJ, Wang S, Brugnara C, Lodish HF: Fetal anemia and apoptosis of red cell progenitors in Stat5a(-\/-)5b(-\/-) mice: A direct role for Stat5 in Bcl-X-L induction. Cell. 1999, 98 (2): 181-191. 10.1016\/S0092-8674(00)81013-2.","journal-title":"Cell"},{"issue":"2","key":"2995_CR50","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1101\/gad.11.2.179","volume":"11","author":"XW Liu","year":"1997","unstructured":"Liu XW, Robinson GW, Wagner KU, Garrett L, WynshawBoris A, Hennighausen L: Stat5a is mandatory for adult mammary gland development and lactogenesis. Gene Dev. 1997, 11 (2): 179-186. 10.1101\/gad.11.2.179.","journal-title":"Gene Dev"},{"issue":"11","key":"2995_CR51","doi-asserted-by":"publisher","first-page":"7421","DOI":"10.1074\/jbc.274.11.7421","volume":"274","author":"SH Park","year":"1999","unstructured":"Park SH, Liu X, Hennighausen L, Davey HW, Waxman DJ: Distinctive roles of STAT5a and STAT5b in sexual dimorphism of hepatic P450 gene expression. Impact of STAT5a gene disruption. J Biol Chem. 1999, 274 (11): 7421-7430. 10.1074\/jbc.274.11.7421.","journal-title":"J Biol Chem"},{"issue":"12","key":"2995_CR52","doi-asserted-by":"publisher","first-page":"3421","DOI":"10.1182\/blood-2009-11-255232","volume":"117","author":"EA Nelson","year":"2011","unstructured":"Nelson EA, Walker SR, Weisberg E, Bar-Natan M, Barrett R, Gashin LB, Terrell S, Klitgaard JL, Santo L, Addorio MR, et al: The STAT5 inhibitor pimozide decreases survival of chronic myelogenous leukemia cells resistant to kinase inhibitors. Blood. 2011, 117 (12): 3421-3429. 10.1182\/blood-2009-11-255232.","journal-title":"Blood"},{"issue":"12","key":"2995_CR53","doi-asserted-by":"publisher","first-page":"3409","DOI":"10.1182\/blood-2009-10-248211","volume":"117","author":"W Warsch","year":"2011","unstructured":"Warsch W, Kollmann K, Eckelhart E, Fajmann S, Cerny-Reiterer S, Holbl A, Gleixner KV, Dworzak M, Mayerhofer M, Hoermann G, et al: High STAT5 levels mediate imatinib resistance and indicate disease progression in chronic myeloid leukemia. Blood. 2011, 117 (12): 3409-3420. 10.1182\/blood-2009-10-248211.","journal-title":"Blood"},{"issue":"8","key":"2995_CR54","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1111\/j.1440-1681.1997.tb02101.x","volume":"24","author":"JP Liu","year":"1997","unstructured":"Liu JP: Protein phosphorylation events in exocytosis and endocytosis. Clin Exp Pharmacol Physiol. 1997, 24 (8): 611-618. 10.1111\/j.1440-1681.1997.tb02101.x.","journal-title":"Clin Exp Pharmacol Physiol"},{"issue":"27","key":"2995_CR55","doi-asserted-by":"publisher","first-page":"16729","DOI":"10.1074\/jbc.272.27.16729","volume":"272","author":"H Li","year":"1997","unstructured":"Li H, Zhao LL, Funder JW, Liu JP: Protein phosphatase 2A inhibits nuclear telomerase activity in human breast cancer cells. J Biol Chem. 1997, 272 (27): 16729-16732. 10.1074\/jbc.272.27.16729.","journal-title":"J Biol Chem"},{"issue":"10","key":"2995_CR56","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1016\/S0960-9822(00)00483-8","volume":"10","author":"S Kharbanda","year":"2000","unstructured":"Kharbanda S, Kumar V, Dhar S, Pandey P, Chen C, Majumder P, Yuan ZM, Whang Y, Strauss W, Pandita TK, et al: Regulation of the hTERT telomerase catalytic subunit by the c-Abl tyrosine kinase. Curr Biol. 2000, 10 (10): 568-575. 10.1016\/S0960-9822(00)00483-8.","journal-title":"Curr Biol"},{"issue":"7","key":"2995_CR57","doi-asserted-by":"publisher","first-page":"2332","DOI":"10.1182\/blood-2006-02-004580","volume":"108","author":"HA Bradeen","year":"2006","unstructured":"Bradeen HA, Eide CA, O'Hare T, Johnson KJ, Willis SG, Lee FY, Druker BJ, Deininger MW: Comparison of imatinib mesylate, dasatinib (BMS-354825), and nilotinib (AMN107) in an N-ethyl-N-nitrosourea (ENU)-based mutagenesis screen: high efficacy of drug combinations. Blood. 2006, 108 (7): 2332-2338. 10.1182\/blood-2006-02-004580.","journal-title":"Blood"},{"issue":"8","key":"2995_CR58","doi-asserted-by":"publisher","first-page":"3279","DOI":"10.1182\/blood-2005-08-3087","volume":"107","author":"M Scherr","year":"2006","unstructured":"Scherr M, Chaturvedi A, Battmer K, Dallmann I, Schultheis B, Ganser A, Eder M: Enhanced sensitivity to inhibition of SHP2, STAT5, and Gab2 expression in chronic myeloid leukemia (CML). Blood. 2006, 107 (8): 3279-3287. 10.1182\/blood-2005-08-3087.","journal-title":"Blood"},{"issue":"9","key":"2995_CR59","doi-asserted-by":"publisher","first-page":"2846","DOI":"10.1182\/blood.V97.9.2846","volume":"97","author":"NJ Donato","year":"2001","unstructured":"Donato NJ, Wu JY, Zhang L, Kantarjian H, Talpaz M: Down-regulation of interleukin-3\/granulocyte-macrophage colony-stimulating factor receptor beta-chain in BCR-ABL(+) human leukemic cells: association with loss of cytokine-mediated Stat-5 activation and protection from apoptosis after BCR-ABL inhibition. Blood. 2001, 97 (9): 2846-2853. 10.1182\/blood.V97.9.2846.","journal-title":"Blood"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2407-11-512.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/1471-2407-11-512\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2407-11-512","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2407-11-512.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,2]],"date-time":"2021-09-02T21:11:37Z","timestamp":1630617097000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/1471-2407-11-512"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,12]]},"references-count":59,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2011,12]]}},"alternative-id":["2995"],"URL":"https:\/\/doi.org\/10.1186\/1471-2407-11-512","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,12]]},"assertion":[{"value":"19 July 2011","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 December 2011","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 December 2011","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"512"}}